Brokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Price Target at $10.10

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have received an average recommendation of “Moderate Buy” from the seven analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $10.10.

CRDF has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiff Oncology in a report on Wednesday, January 21st. Piper Sandler decreased their price objective on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Wall Street Zen upgraded Cardiff Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday. Noble Financial started coverage on Cardiff Oncology in a report on Monday, January 5th. They set an “outperform” rating and a $12.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Cardiff Oncology in a research report on Wednesday, January 28th.

Institutional Trading of Cardiff Oncology

Hedge funds have recently modified their holdings of the company. Capital Advisors Wealth Management LLC purchased a new position in Cardiff Oncology during the 4th quarter worth $30,000. Tamar Securities LLC purchased a new position in Cardiff Oncology in the 4th quarter worth $32,000. Jeppson Wealth Management LLC purchased a new stake in Cardiff Oncology during the 3rd quarter valued at about $25,000. Brooklyn Investment Group purchased a new position in shares of Cardiff Oncology in the third quarter worth about $26,000. Finally, R Squared Ltd purchased a new stake in shares of Cardiff Oncology in the 4th quarter valued at $36,000. 16.29% of the stock is owned by hedge funds and other institutional investors.

Cardiff Oncology Trading Up 0.5%

NASDAQ:CRDF opened at $1.88 on Monday. The stock has a market capitalization of $128.52 million, a PE ratio of -2.72 and a beta of 1.32. The firm’s 50 day moving average is $2.21 and its 200 day moving average is $2.23. Cardiff Oncology has a 12 month low of $1.48 and a 12 month high of $4.56.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.07. Cardiff Oncology had a negative net margin of 7,733.22% and a negative return on equity of 82.01%. The business had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.13 million. Research analysts predict that Cardiff Oncology will post -0.99 earnings per share for the current year.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.